GLAXOSMITHKLINE PLC | CIK:0001131399 | 3

  • Filed: 3/20/2018
  • Entity registrant name: GLAXOSMITHKLINE PLC (CIK: 0001131399)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1131399/000119312518088407/0001193125-18-088407-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1131399/000119312518088407/gsk-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001131399
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory

    Research and development

    Research and development expenditure is charged to the income statement in the period in which it is incurred. Development expenditure is capitalised when the criteria for recognising an asset are met, usually when a regulatory filing has been made in a major market and approval is considered highly probable. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group’s policy.